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Obesity is characterized by a state of low-grade, chronic inflammation. Wang et al. (2014) report that immune
cells from obese mice have decreased production of IL-22, a cytokine involved in immune responses
and inflammation, and reveal therapeutic effects of exogenous IL-22 against obesity-linked metabolic dys-
functions.Obesity is associated with increased
inflammation, which is mainly evidenced
by accumulation and proinflammatory
polarization of macrophages/dendritic
cells (DCs) and T cells in adipose tissue
and skeletal muscle, and contributes to
the development of insulin resistance
and type 2 diabetes (Glass and Olefsky,
2012; Kratz et al., 2014; Wu et al., 2007).
While alternatively activated macro-
phages, regulatory T cells, eosinophils,
and invariant natural killer T cells are resi-
dent cells in lean adipose tissue and
decreased in obese adipose tissue, ‘‘clas-
sically activated-like’’ or ‘‘metabolically
activated,’’ proinflammatory macro-
phages, T-cytotoxic 1 and T helper type
1 cells, neutrophils, B cells, andmast cells
are increased in obese adipose tissue and
mediate adipose tissue inflammation
(Glass and Olefsky, 2012; Kratz et al.,
2014). The mechanisms whereby inflam-
mation contributes to obesity-linked
metabolic dysfunctions remain incom-
pletely understood. Increased secretion
of proinflammatory cytokinesmay directly
influence metabolic functions of insulin-
responsive tissues/cells such as adipo-
cytes and myocytes, causing insulin
resistance in these tissues/cells. Adverse
effects of proinflammatory cells/mole-
cules on adipocytes/preadipocytes may
also accelerate lipid transfer from adipo-
cytes to skeletal muscle and liver, leading
to ectopic lipid deposition and insulin
resistance in these tissues and causing
systemic metabolic dysfunctions (Glass
and Olefsky, 2012; Wu et al., 2007).
Therefore, anti-inflammation therapy is
viewed as a promising strategy for
obesity-linked metabolic dysfunctions
and has indeed shown some promising708 Cell Metabolism 20, November 4, 2014 ªeffects (Glass and Olefsky, 2012). In
contrast, Wang et al. (2014) now report
impaired IL-22 induction in immune
cells, leading to compromised host de-
fense, in obese mice and unexpected
beneficial effects of exogenous initerleu-
kin-22 (IL-22) on obesity-related meta-
bolic dysfunctions.
IL-22 is a cytokine mostly produced by
activated DCs, innate lymphoid cells,
and activated T cells, including Th22,
Th17, and Th1 cells, that initiates immune
responses against bacterial pathogens
especially in epithelial cells (Sabat et al.,
2014). IL-22 is thought to function as a
proinflammatory cytokine, as it induces
the production of leukocyte-attracting
chemokines and acute-phase proteins in
epithelial cells or hepatocytes (Sabat
et al., 2014), which helps amplify the in-
flammatory process andenhancesantimi-
crobial immunity. Indeed, recent reports
showed increased Th22 frequency and
IL-22 level in blood and enrichment of IL-
22- and IL-17-producing T cells in adipose
tissue of obese diabetic patients (Dalmas
et al., 2014). Macrophage-derived IL-1b
promoted adipose tissue T cell production
of IL-22, which in turn increased macro-
phage release of IL-1b (Dalmas et al.,
2014). Therefore, IL-22 may mediate
amplification of IL-1b-driven adipose tis-
sue inflammation and contribute to
obesity-linked metabolic dysfunctions.
Recent studies have also recognized a
connection between altered gut micro-
biota and obesity-related metabolic
dysfunctions (Tremaroli and Ba¨ckhed,
2012). Because of its crucial role in
mucosal host defense, Wang et al.
(2014) studied the biological importance
of IL-22 production from immune cells in2014 Elsevier Inc.obesemice. In contrast to the reported in-
creases in IL-22-producing T cells in
blood and adipose tissue of obese hu-
mans (Dalmas et al., 2014), Wang et al.
(2014) observed a defect in IL-22 induc-
tion in immune cells of diet-induced
obese (DIO) mice and genetically obese
leptin-deficient (ob/ob), or leptin recep-
tor-deficient (db/db) mice under various
immune challenges, which led to
increased susceptibility to C. rodentium
infection in these mice. Unexpectedly,
they further demonstrated that deletion
of IL-22 receptor caused greater weight
gain and worsened insulin resistance in
DIO mice. Treatment of DIO and db/db
mice with exogenous IL-22 decreased
food intake, reduced body weight and
fat mass, and reversed obesity-related
metabolic dysfunctions, with significant
improvement of hyperglycemia and insu-
lin resistance. Intriguingly, IL-22 treatment
of DIO or db/db mice reduced serum lipo-
polysaccharide (LPS) levels, decreased
adipose tissue inflammation, and acti-
vated STAT3 in liver and adipose tissue
with improved lipid metabolism, including
prevention of hepatic steatosis and in-
duction of expression of genes involved
in triglyceride lipolysis and fatty acid
b-oxidation.
Multiple downstream functions of
IL-22, including maintaining mucosal
epithelial integrity, reducing inflammation,
and alleviating metabolic functions, may
all contribute to the beneficial effects of
this cytokine on obesity-linked metabolic
dysfunctions (Wang et al., 2014). The re-
ductions in body weight and LPS levels
observed in obese mice treated with
IL-22 may have caused the decreased
adipose tissue inflammation in the study
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sults seem to oppose previous studies
supporting a proinflammatory role of IL-
22 in adipose tissue in humans and mice
(Dalmas et al., 2014; Wang et al., 2011).
The reasons for these IL-22-induced ef-
fects, weight reduction in particular,
remain unknown and may be linked to
the restoration of mucosal immunity.
However, disruption of mucosal immunity
by ablation of lymphotoxin has been
shown to decrease IL-22 and reduce
weight gain in DIO mice, whereas delivery
of exogenous IL-22 restored weight gain
in these mice (Upadhyay et al., 2012).
These results point to an essential role of
mucosal immunity mediated by the lym-
photoxin-IL-22 pathway in weight gain,
rather than weight loss, in DIO mice. In
addition, Wang et al. (2014) found that
STAT3 activation was associated with
improved metabolism in liver and adipose
tissue of obese mice treated with IL-22.
However, previous studies do not support
a beneficial role of STAT3 in hepatocyte
and adipocyte metabolisms. In fact,
STAT3 activation may mediate hepato-
cyte and adipocyte insulin resistance
induced by IL-6, which is increased in
obesity (Kristiansen and Mandrup-Poul-
sen, 2005). Therefore, further studies are
needed to define the exact mechanisms
whereby IL-22 treatment improvesobesity-linked metabolic functions. In
particular, it needs to be determined
how IL-22 treatment of obese mice
causes reductions in body weight and
fat mass, which could account for most
of the observed beneficial effects. Weight
reduction by IL-22 cannot be explained
solely by reduced food intake, as IL-22
treatment still decreased body weight in
DIO mice in pair-feeding studies with
normalized food intake (Wang et al.,
2014). Therefore, effects of IL-22 on en-
ergy expenditure, and potential direct
effects on metabolism of preadipocytes/
adipocytes and skeletal muscle as well
as their mechanisms, remain to be
investigated.
A key challenge is now to determine
whether IL-22 can be used as a therapy
for obesity in humans. The study by
Wang et al. (2014) supports this possibil-
ity, though IL-22 and constitutive activa-
tion of the STAT3 pathway have been
involved in several types of human can-
cers (Sabat et al., 2014) and IL-22 overex-
pression in mouse adipose tissue results
in spontaneous liposarcoma (Wang
et al., 2011). Therefore, a better under-
standing of IL-22 mechanisms of action
and examination of the potential onco-
genic side effects are warranted before
IL-22 can be used in humans for
obesity-associated metabolic diseases.Cell Metabolism 20,REFERENCES
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